NMD Pharma, a neuromuscular disorder-focused spinout from Aarhus University, secured $47m in a round co-led by Roche and backed by Novo and Lundbeck.
Denmark-based neuromuscular disorder drug developer NMD Pharma raised €38m ($47m) on Friday in a series A round co-led by Roche Venture Fund, the corporate venturing arm of healthcare company Roche.
Venture capital firm Inkef Capital co-led the round, which also featured Novo Seeds and Lundbeckfonden Emerge, respective early-stage investment units for pharmaceutical firms Novo and Lundbeck.
Founded in 2015, NMD Pharma is developing treatments for neuromuscular disorders that can cause debilitating fatigue and weakness, potentially leading to life-threatening respiratory issues.
…
